Neion Bio Strikes Initial Biosimilars Deal For Its Egg-Based Platform

Firm’s Raptor Platform Uses Eggs To Produce Recombinant Biologics

 
• By Dave Wallace
  
Neion Bio’s Raptor platform uses eggs to produce recombinant biologics (Shutterstock)

More from Deals

More from Business